I. U1018, . Center, . Research, P. Epidemiology, and . Health, UMRS 1018, 16av. Paul Vaillant Couturier, 94807 Villejuif Cédex, France. 3 INSERM U1147, Univ Paris Sorbonne Cité UMRS Polyclinique Saint Privat Clinique Beau Soleil, vol.775, issue.4 6 7 9 10

. Invs, Projections de l'incidence et de la mortalité par cancer en France en 2011. Rapport technique. Saint-Maurice: Institut de veille sanitaire, 2011.

A. Hsing, L. Tsao, and S. Devesa, International trends and patterns of prostate cancer incidence and mortality, International Journal of Cancer, vol.85, issue.1, pp.60-67, 2000.
DOI : 10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B

D. Bostwick, H. Burke, D. Djakiew, S. Euling, S. Ho et al., Human prostate cancer risk factors, Cancer, vol.17, issue.S10, pp.2371-2490, 2004.
DOI : 10.1002/cncr.20408

A. Hsing and A. Chokkalingam, Table of Contents, Front Biosci, vol.11, pp.1388-1413, 2006.
DOI : 10.3726/978-1-4539-1214-0/3

A. Hsing and S. Devesa, Trends and Patterns of Prostate Cancer: What Do They Suggest?, Epidemiologic Reviews, vol.23, issue.1, pp.3-13, 2001.
DOI : 10.1093/oxfordjournals.epirev.a000792

A. Hsing, L. Sakoda, and S. Chua, Obesity, metabolic syndrome, and prostate cancer, Am J Clin Nutr, vol.86, pp.843-857, 2007.

J. Lee, K. Demissie, S. Lu, and G. Rhoads, Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea, Cancer Control, vol.14, pp.78-85, 2007.

R. Stevens, J. Hansen, G. Costa, E. Haus, T. Kauppinen et al., Considerations of circadian impact for defining 'shift work' in cancer studies: IARC Working Group Report, cancer studies: IARC Working Group Report, pp.154-162, 2011.
DOI : 10.1136/oem.2009.053512

H. Kolstad, Nightshift work and risk of breast cancer and other cancers???a critical review of the epidemiologic evidence, Scandinavian Journal of Work, Environment & Health, vol.34, issue.1, pp.5-22, 2008.
DOI : 10.5271/sjweh.1194

G. Costa, E. Haus, and R. Stevens, Shift work and cancer ??? considerations on rationale, mechanisms, and epidemiology, Scandinavian Journal of Work, Environment & Health, vol.36, issue.2, pp.163-179, 2010.
DOI : 10.5271/sjweh.2899

L. Fritschi, D. Glass, J. Heyworth, K. Aronson, J. Girschik et al., Hypotheses for mechanisms linking shiftwork and cancer, Medical Hypotheses, vol.77, issue.3, pp.430-436, 2011.
DOI : 10.1016/j.mehy.2011.06.002

L. Sigurdardottir, U. Valdimarsdottir, K. Fall, J. Rider, S. Lockley et al., Circadian Disruption, Sleep Loss, and Prostate Cancer Risk: A Systematic Review of Epidemiologic Studies, Cancer Epidemiology Biomarkers & Prevention, vol.21, issue.7, pp.1002-1011, 2012.
DOI : 10.1158/1055-9965.EPI-12-0116

T. Kubo, K. Ozasa, K. Mikami, K. Wakai, Y. Fujino et al., Prospective Cohort Study of the Risk of Prostate Cancer among Rotating-Shift Workers: Findings from the Japan Collaborative Cohort Study, American Journal of Epidemiology, vol.164, issue.6, pp.549-555, 2006.
DOI : 10.1093/aje/kwj232

M. Conlon, N. Lightfoot, and N. Kreiger, Rotating Shift Work and Risk of Prostate Cancer, Epidemiology, vol.18, issue.1, pp.182-183, 2007.
DOI : 10.1097/01.ede.0000249519.33978.31

T. Kubo, I. Oyama, T. Nakamura, M. Kunimoto, K. Kadowaki et al., Industry-based retrospective cohort study of the risk of prostate cancer among rotating-shift workers, International Journal of Urology, vol.17, issue.3, pp.206-211, 2011.
DOI : 10.1111/j.1442-2042.2010.02714.x

M. Parent, M. El-zein, M. Rousseau, J. Pintos, and J. Siemiatycki, Night Work and the Risk of Cancer Among Men, American Journal of Epidemiology, vol.176, issue.9, pp.751-759, 2012.
DOI : 10.1093/aje/kws318

URL : https://hal.archives-ouvertes.fr/pasteur-01009351

A. Buja, J. Lange, E. Perssinotto, G. Rausa, F. Grigoletto et al., Cancer incidence among male military and civil pilots and flight attendants: an analysis on published data, Toxicology and Industrial Health, vol.158, issue.1, pp.273-282, 2005.
DOI : 10.1191/0748233705th238oa

M. Kakizaki, K. Inoue, S. Kuriyama, T. Sone, K. Matsuda-ohmori et al., Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study, British Journal of Cancer, vol.73, issue.1, pp.176-178, 2008.
DOI : 10.1016/j.smrv.2003.10.002

F. Balkwill and A. Mantovani, Inflammation and cancer: back to Virchow? Lancet, pp.539-545, 2001.

L. Coussens and Z. Werb, Inflammatory Cells and Cancer, The Journal of Experimental Medicine, vol.54, issue.6, pp.23-26, 2001.
DOI : 10.1073/pnas.95.16.9325

L. Coussens and Z. Werb, Inflammation and cancer, Nature, vol.2, issue.6917, pp.860-867, 2002.
DOI : 10.1006/cyto.1996.0074

D. Marzo, A. Marchi, V. Epstein, J. Nelson, and W. , Proliferative Inflammatory Atrophy of the Prostate, The American Journal of Pathology, vol.155, issue.6, pp.1985-1992, 1999.
DOI : 10.1016/S0002-9440(10)65517-4

D. Marzo, A. Nakai, Y. Nelson, and W. , Inflammation, atrophy, and prostate carcinogenesis, Urologic Oncology: Seminars and Original Investigations, vol.25, issue.5, pp.398-400, 2007.
DOI : 10.1016/j.urolonc.2007.05.007

D. Marzo, A. Platz, E. Sutcliffe, S. Xu, J. Grönberg et al., Inflammation in prostate carcinogenesis, Nature Reviews Cancer, vol.175, issue.4, pp.256-269, 2007.
DOI : 10.1038/nrc2090

L. Dennis, C. Lynch, and J. Torner, Epidemiologic association between prostatitis and prostate cancer, Urology, vol.60, issue.1, pp.78-83, 2002.
DOI : 10.1016/S0090-4295(02)01637-0

L. Dennis and D. Dawson, Meta-Analysis of Measures of Sexual Activity and Prostate Cancer, Epidemiology, vol.13, issue.1, pp.72-79, 2002.
DOI : 10.1097/00001648-200201000-00012

R. Hayes, L. Pottern, H. Strickler, C. Rabkin, V. Pope et al., Sexual behaviour, STDs and risks for prostate cancer, British Journal of Cancer, vol.82, issue.3, pp.718-725, 2000.
DOI : 10.1054/bjoc.1999.0986

D. Drachenberg, A. Elgamal, R. Rowbotham, M. Peterson, and G. Murphy, Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer, The Prostate, vol.57, issue.2, pp.127-133, 1999.
DOI : 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H

R. Veltri, M. Miller, G. Zhao, A. Ng, G. Marley et al., Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer, Urology, vol.53, issue.1, pp.139-147, 1999.
DOI : 10.1016/S0090-4295(98)00455-5

S. Shariat, B. Andrews, M. Kattan, J. Kim, T. Wheeler et al., Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis, Urology, vol.58, issue.6, pp.1008-1015, 2001.
DOI : 10.1016/S0090-4295(01)01405-4

J. Carpten, N. Nupponen, S. Isaacs, R. Sood, C. Robbins et al., Germline mutations in the ribonuclease L gene in families showing linkage with HPC1, Nature Genetics, vol.30, issue.2, pp.181-184, 2002.
DOI : 10.1038/ng823

R. Silverman, Implications for RNase L in Prostate Cancer Biology, Biochemistry, vol.42, issue.7, pp.1805-1812, 2003.
DOI : 10.1021/bi027147i

D. Michaud, S. Daugherty, S. Berndt, M. Yeager, E. Crawford et al., Genetic Polymorphisms of Interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and Risk of Prostate Cancer, Cancer Research, vol.66, issue.8, pp.4525-4530, 2006.
DOI : 10.1158/0008-5472.CAN-05-3987

C. Bosetti, S. Gallus, L. Vecchia, and C. , Aspirin and cancer risk: an updated quantitative review to 2005, Cancer Causes & Control, vol.13, issue.7, pp.871-888, 2006.
DOI : 10.1007/s10552-006-0033-7

J. Cuzick, F. Otto, J. Baron, P. Brown, J. Burn et al., Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement, The Lancet Oncology, vol.10, issue.5, pp.501-507, 2009.
DOI : 10.1016/S1470-2045(09)70035-X

C. Bosetti, V. Rosato, S. Gallus, J. Cuzick, L. Vecchia et al., Aspirin and cancer risk: a quantitative review to 2011, Annals of Oncology, vol.23, issue.6, pp.1403-1415, 2012.
DOI : 10.1093/annonc/mds113

S. Gupta, M. Srivastava, N. Ahmad, D. Bostwick, and H. Mukhtar, Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma, The Prostate, vol.73, issue.20, pp.73-78, 2000.
DOI : 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G

T. Hussain, S. Gupta, and H. Mukhtar, Cyclooxygenase-2 and prostate carcinogenesis, Cancer Letters, vol.191, issue.2, pp.125-135, 2003.
DOI : 10.1016/S0304-3835(02)00524-4

A. Chaudry, K. Wahle, S. Mcclinton, and L. Moffat, Arachidonic acid metabolism in benign and malignant prostatic tissuein vitro: Effects of fatty acids and cyclooxygenase inhibitors, International Journal of Cancer, vol.81, issue.2, pp.176-180, 1994.
DOI : 10.1002/ijc.2910570208

R. Dubois, Cyclooxygenase-2 Selective Inhibitors and Prostate Cancer: What Is the Clinical Benefit?, Journal of Clinical Oncology, vol.24, issue.18, pp.2691-2693, 2006.
DOI : 10.1200/JCO.2006.05.9709

P. Mathew, Inflammatory Pathogenesis of Prostate Cancer and Celecoxib, Journal of Clinical Oncology, vol.28, issue.12, pp.197-198, 2010.
DOI : 10.1200/JCO.2009.27.1098

A. Nomura, G. Stemmermann, P. Chyou, B. Henderson, and F. Stanczyk, Serum androgens and prostate cancer, Cancer Epidemiol Biomark Prev, vol.5, pp.621-625, 1996.

A. Hsing, Hormones and Prostate Cancer: Where Do We Go From Here?, JNCI Journal of the National Cancer Institute, vol.88, issue.16, pp.1093-1095, 1996.
DOI : 10.1093/jnci/88.16.1093

N. Eaton, G. Reeves, P. Appleby, and T. Key, Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies, British Journal of Cancer, vol.80, issue.7, pp.930-934, 1999.
DOI : 10.1038/sj.bjc.6690445

A. Hsing, L. Chu, and F. Stanczyk, Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomark Prev, pp.2525-2530, 2008.

A. Roddam, N. Allen, P. Appleby, and T. Key, Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies, J Natl Cancer Inst, vol.100, pp.170-183, 2008.

D. Wigle, M. Turner, J. Gomes, and M. Parent, Role of Hormonal and Other Factors in Human Prostate Cancer, Journal of Toxicology and Environmental Health, Part B, vol.13, issue.1, pp.242-259, 2008.
DOI : 10.1093/aje/kwh139

R. Cremers, K. Aben, S. Vermeulen, D. Heijer, M. et al., Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer, European Journal of Cancer, vol.46, issue.18, pp.3294-3299, 2010.
DOI : 10.1016/j.ejca.2010.05.020

Y. Ruhayel, A. Giwercman, D. Ulmert, L. Rylander, A. Bjartell et al., Male infertility and prostate cancer risk: a nested case???control study, Cancer Causes & Control, vol.362, issue.10, pp.1635-1643, 2010.
DOI : 10.1007/s10552-010-9592-8

J. Wright, S. Page, D. Lin, and J. Stanford, Male pattern baldness and prostate cancer risk in a population-based case???control study, Cancer Epidemiology, vol.34, issue.2, pp.131-135, 2010.
DOI : 10.1016/j.canep.2010.02.003

M. Yassa, M. Saliou, Y. De-rycke, C. Hemery, M. Henni et al., Male pattern baldness and the risk of prostate cancer, Annals of Oncology, vol.22, issue.8, pp.1824-1827, 2011.
DOI : 10.1093/annonc/mdq695

A. Hsing, S. Chua, Y. Gao, E. Gentzschein, L. Chang et al., Prostate Cancer Risk and Serum Levels of Insulin and Leptin: a Population-Based Study, JNCI Journal of the National Cancer Institute, vol.93, issue.10, pp.783-789, 2001.
DOI : 10.1093/jnci/93.10.783

M. Pollak, Insulin-like Growth Factors and Prostate Cancer, Epidemiologic Reviews, vol.23, issue.1, pp.59-66, 2001.
DOI : 10.1093/oxfordjournals.epirev.a000796

URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=

I. Gorbachinsky, H. Akpinar, and D. Assimos, Metabolic syndrome and urologic diseases, Rev Urol, vol.12, pp.157-180, 2010.

L. Wallner, H. Morgenstern, M. Mcgree, D. Jacobson, S. Sauver et al., The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study, BJU International, vol.66, issue.6, pp.929-935, 2011.
DOI : 10.1111/j.1464-410X.2010.09703.x

E. Kassi, P. Pervanidou, G. Kaltsas, and G. Chrousos, Metabolic syndrome: definitions and controversies, BMC Medicine, vol.163, issue.Suppl 3, p.48, 2011.
DOI : 10.1001/archinte.163.4.427

D. Nunzio, C. Aronson, W. Freedland, S. Giovannucci, E. Parsons et al., The Correlation Between Metabolic Syndrome and Prostatic Diseases, European Urology, vol.61, issue.3, pp.560-570, 2012.
DOI : 10.1016/j.eururo.2011.11.013

I. Vucenik and J. Stains, Obesity and cancer risk: evidence, mechanisms, and recommendations, Annals of the New York Academy of Sciences, vol.17, issue.1, pp.37-43, 2012.
DOI : 10.1111/j.1749-6632.2012.06750.x

E. Jacobs and S. Gapstur, Cholesterol and Cancer: Answers and New Questions, Cancer Epidemiology Biomarkers & Prevention, vol.18, issue.11, pp.2805-2806, 2009.
DOI : 10.1158/1055-9965.EPI-09-1027

I. Agalliu, C. Salinas, P. Hansten, E. Ostrander, and J. Stanford, Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study, American Journal of Epidemiology, vol.168, issue.3, pp.250-260, 2008.
DOI : 10.1093/aje/kwn141

D. Bansal, K. Undela, D. Cruz, S. Schifano, and F. , Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies, PLoS ONE, vol.7, issue.10, p.46691, 2012.
DOI : 10.1371/journal.pone.0046691.s001

E. Platz, C. Till, P. Goodman, H. Parnes, W. Figg et al., Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial, Cancer Epidemiology Biomarkers & Prevention, vol.18, issue.11, pp.2807-2813, 2009.
DOI : 10.1158/1055-9965.EPI-09-0472

B. Carter, T. Beaty, G. Steinberg, B. Childs, and P. Walsh, Mendelian inheritance of familial prostate cancer., Proceedings of the National Academy of Sciences, vol.89, issue.8, pp.3367-3371, 1992.
DOI : 10.1073/pnas.89.8.3367

E. Ostrander and J. Stanford, Genetics of Prostate Cancer: Too Many Loci, Too Few Genes, The American Journal of Human Genetics, vol.67, issue.6, pp.1367-1375, 2000.
DOI : 10.1086/316916

O. Cussenot and A. Valeri, Heterogeneity in genetic susceptibility to prostate cancer, European Journal of Internal Medicine, vol.12, issue.1, pp.11-16, 2001.
DOI : 10.1016/S0953-6205(00)00136-9

T. Rebbeck, Inherited genotype and prostate cancer outcomes, Cancer Epidemiol Biomark Prev, vol.1110, issue.1, pp.945-952, 2002.

D. Schaid, The complex genetic epidemiology of prostate cancer, Human Molecular Genetics, vol.13, issue.90001, pp.103-121, 2004.
DOI : 10.1093/hmg/ddh072

B. Rybicki, D. Ph, C. Neslund-dudas, N. Nock, L. Schultz et al., Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism, Cancer Detection and Prevention, vol.30, issue.5, pp.412-422, 2006.
DOI : 10.1016/j.cdp.2006.09.004

Y. Zhu, T. Zheng, R. Stevens, Y. Zhang, and P. Boyle, Does " clock " matter in prostate cancer? Cancer Epidemiol Biomark Prev, pp.3-5, 2006.

R. Golden and R. Kimbrough, Weight of Evidence Evaluation of Potential Human Cancer Risks from Exposure to Polychlorinated Biphenyls: An Update Based on Studies Published Since 2003, Critical Reviews in Toxicology, vol.9, issue.17, pp.299-331, 2009.
DOI : 10.1210/me.2006-0007

Y. Zhu, R. Stevens, A. Hoffman, L. Fitzgerald, E. Kwon et al., Testing the Circadian Gene Hypothesis in Prostate Cancer: A Population-Based Case-Control Study, Cancer Research, vol.69, issue.24, pp.9315-9322, 2009.
DOI : 10.1158/0008-5472.CAN-09-0648

L. Chu, Y. Zhu, K. Yu, T. Zheng, A. Chokkalingam et al., Correlation between Circadian Gene Variants and Serum Levels of Sex Steroids and Insulin-like Growth Factor-I, Cancer Epidemiology Biomarkers & Prevention, vol.17, issue.11, pp.3268-3273, 2008.
DOI : 10.1158/1055-9965.EPI-08-0073

A. Villers, B. Malavaud, X. Rebillard, V. Bataille, and F. Iborra, ERSPC: features and preliminary results of France, BJU International, vol.13, issue.s2, pp.27-29, 2003.
DOI : 10.1111/j.1464-410X.2003.04392.x

F. Schröder, J. Hugosson, M. Roobol, T. Tammela, S. Ciatto et al., Prostate-Cancer Mortality at 11 Years of Follow-up, New England Journal of Medicine, vol.366, issue.11, pp.981-990, 2012.
DOI : 10.1056/NEJMoa1113135

M. Spitz, X. Wu, and G. Mills, Integrative Epidemiology: From Risk Assessment to Outcome Prediction, Journal of Clinical Oncology, vol.23, issue.2, pp.267-275, 2005.
DOI : 10.1200/JCO.2005.05.122

M. Spitz, N. Caporaso, and T. Sellers, Integrative Cancer Epidemiology--The Next Generation, Cancer Discovery, vol.2, issue.12, pp.1087-1090, 2012.
DOI : 10.1158/2159-8290.CD-12-0424